Literature DB >> 6134442

High-dosage anticholinergic therapy in dystonia.

S Fahn.   

Abstract

Twenty-three children and 52 adults with torsion dystonia of various etiologies and distribution patterns of the involuntary movements were treated in an open-label study with anticholinergic medication. The dosage was build up gradually until there was either benefit or tolerable adverse effect. Trihexyphenidyl was used initially, but beginning in 1979, ethopropazine was utilized in the adult subjects. Significant benefit occurred in 61% of children and in 38% of adults.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6134442

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


  5 in total

Review 1.  The neurobiological basis for novel experimental therapeutics in dystonia.

Authors:  Anthony M Downs; Kaitlyn M Roman; Simone A Campbell; Antonio Pisani; Ellen J Hess; Paola Bonsi
Journal:  Neurobiol Dis       Date:  2019-07-04       Impact factor: 5.996

Review 2.  Emerging concepts in the physiological basis of dystonia.

Authors:  Angelo Quartarone; Mark Hallett
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

3.  Developmental profile of the aberrant dopamine D2 receptor response in striatal cholinergic interneurons in DYT1 dystonia.

Authors:  Giuseppe Sciamanna; Annalisa Tassone; Giuseppina Martella; Georgia Mandolesi; Francesca Puglisi; Dario Cuomo; Grazia Madeo; Giulia Ponterio; David George Standaert; Paola Bonsi; Antonio Pisani
Journal:  PLoS One       Date:  2011-09-02       Impact factor: 3.240

Review 4.  Direct cerebello-striatal loop in dystonia as a possible new target for deep brain stimulation: A revised view of subcortical pathways involved.

Authors:  Ryuji Kaji
Journal:  Front Neurol       Date:  2022-08-24       Impact factor: 4.086

Review 5.  Treating complex movement disorders in children with cerebral palsy.

Authors:  Claire Lundy; Daniel Lumsden; Charlie Fairhurst
Journal:  Ulster Med J       Date:  2009-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.